Claes Andersson

An integrative molecular map of pediatric B-cell precursor acute lymphoblastic leukemia

Krali, Olga; Enblad, Anna Pia; Sulyaeva, Julia; Gogishvili, Dea et al.

Part of Communications Medicine, 2026

• DOI for An integrative molecular map of pediatric B-cell precursor acute lymphoblastic leukemia
• Download full text (pdf) of An integrative molecular map of pediatric B-cell precursor acute lymphoblastic leukemia

Characterization of the anticancer effect of mebendazole and its interaction with standard cytotoxic drugs in patient tumor cells ex vivo and in an in vivo mouse model

Mansoori, Sharmineh; Blom, Kristin; Andersson, Claes; Fryknäs, Mårten et al.

Part of Oncology Reports, 2026

• DOI for Characterization of the anticancer effect of mebendazole and its interaction with standard cytotoxic drugs in patient tumor cells ex vivo and in an in vivo mouse model
• Download full text (pdf) of Characterization of the anticancer effect of mebendazole and its interaction with standard cytotoxic drugs in patient tumor cells ex vivo and in an in vivo mouse model

Extensive analysis of pollutant interactions: Identification of deleterious synergistic effects at environmentally relevant dose levels using Drosophila and mammalian cells

Lagunas-Rangel, Francisco Alejandro; Åberg, Martin; Liao, Sifang; Espinelli-Amorim, Felippe et al.

Part of Science of the Total Environment, 2025

• DOI for Extensive analysis of pollutant interactions: Identification of deleterious synergistic effects at environmentally relevant dose levels using Drosophila and mammalian cells
• Download full text (pdf) of Extensive analysis of pollutant interactions: Identification of deleterious synergistic effects at environmentally relevant dose levels using Drosophila and mammalian cells

Ex vivo drug responses and molecular profiles of 597 pediatric acute lymphoblastic leukemia patients

Enblad, Anna Pia; Krali, Olga; Gezelius, Henrik; Lundmark, Anders et al.

Part of HemaSphere, 2025

• DOI for Ex vivo drug responses and molecular profiles of 597 pediatric acute lymphoblastic leukemia patients
• Download full text (pdf) of Ex vivo drug responses and molecular profiles of 597 pediatric acute lymphoblastic leukemia patients

Exploratory insights from the immuno-oncology hollow fiber assay: A pilot approach bridging In Vitro and In Vivo models

Selvin, Tove; Berglund, Malin; Akerstrom, Anders; Zia, Marco et al.

Part of SLAS TECHNOLOGY, 2024

• DOI for Exploratory insights from the immuno-oncology hollow fiber assay: A pilot approach bridging In Vitro and In Vivo models
• Download full text (pdf) of Exploratory insights from the immuno-oncology hollow fiber assay: A pilot approach bridging In Vitro and In Vivo models

An integrative molecular map of pediatric B-cell precursor acute lymphoblastic leukemia

Krali, Olga; Enblad, Anna Pia; Sulyaeva, Julia; Gogishvili, Dea et al.

Part of Communications Medicine, 2026

• DOI for An integrative molecular map of pediatric B-cell precursor acute lymphoblastic leukemia
• Download full text (pdf) of An integrative molecular map of pediatric B-cell precursor acute lymphoblastic leukemia

Characterization of the anticancer effect of mebendazole and its interaction with standard cytotoxic drugs in patient tumor cells ex vivo and in an in vivo mouse model

Mansoori, Sharmineh; Blom, Kristin; Andersson, Claes; Fryknäs, Mårten et al.

Part of Oncology Reports, 2026

• DOI for Characterization of the anticancer effect of mebendazole and its interaction with standard cytotoxic drugs in patient tumor cells ex vivo and in an in vivo mouse model
• Download full text (pdf) of Characterization of the anticancer effect of mebendazole and its interaction with standard cytotoxic drugs in patient tumor cells ex vivo and in an in vivo mouse model

Extensive analysis of pollutant interactions: Identification of deleterious synergistic effects at environmentally relevant dose levels using Drosophila and mammalian cells

Lagunas-Rangel, Francisco Alejandro; Åberg, Martin; Liao, Sifang; Espinelli-Amorim, Felippe et al.

Part of Science of the Total Environment, 2025

• DOI for Extensive analysis of pollutant interactions: Identification of deleterious synergistic effects at environmentally relevant dose levels using Drosophila and mammalian cells
• Download full text (pdf) of Extensive analysis of pollutant interactions: Identification of deleterious synergistic effects at environmentally relevant dose levels using Drosophila and mammalian cells

Ex vivo drug responses and molecular profiles of 597 pediatric acute lymphoblastic leukemia patients

Enblad, Anna Pia; Krali, Olga; Gezelius, Henrik; Lundmark, Anders et al.

Part of HemaSphere, 2025

• DOI for Ex vivo drug responses and molecular profiles of 597 pediatric acute lymphoblastic leukemia patients
• Download full text (pdf) of Ex vivo drug responses and molecular profiles of 597 pediatric acute lymphoblastic leukemia patients

Exploratory insights from the immuno-oncology hollow fiber assay: A pilot approach bridging In Vitro and In Vivo models

Selvin, Tove; Berglund, Malin; Akerstrom, Anders; Zia, Marco et al.

Part of SLAS TECHNOLOGY, 2024

• DOI for Exploratory insights from the immuno-oncology hollow fiber assay: A pilot approach bridging In Vitro and In Vivo models
• Download full text (pdf) of Exploratory insights from the immuno-oncology hollow fiber assay: A pilot approach bridging In Vitro and In Vivo models

Immuno-oncological effects of standard anticancer agents and commonly used concomitant drugs: an in vitro assessment

Selvin, Tove; Berglund, Malin; Lenhammar, Lena; Lindskog, Magnus et al.

Part of BMC Pharmacology & Toxicology, 2024

• DOI for Immuno-oncological effects of standard anticancer agents and commonly used concomitant drugs: an in vitro assessment
• Download full text (pdf) of Immuno-oncological effects of standard anticancer agents and commonly used concomitant drugs: an in vitro assessment

Comparison of high-throughput single-cell RNA-seq methods for ex vivo drug screening

Gezelius, Henrik; Enblad, Anna Pia; Lundmark, Anders; Åberg, Martin et al.

Part of NAR Genomics and Bioinformatics, 2024

• DOI for Comparison of high-throughput single-cell RNA-seq methods for ex vivo drug screening
• Download full text (pdf) of Comparison of high-throughput single-cell RNA-seq methods for ex vivo drug screening

Phenotypic screening platform identifies statins as enhancers of immune cell-induced cancer cell death

Selvin, Tove; Berglund, Malin; Lenhammar, Lena; Jarvius, Malin et al.

Part of BMC Cancer, 2023

• DOI for Phenotypic screening platform identifies statins as enhancers of immune cell-induced cancer cell death
• Download full text (pdf) of Phenotypic screening platform identifies statins as enhancers of immune cell-induced cancer cell death

Ex vivo assessment of chemotherapy sensitivity of colorectal cancer peritoneal metastases

Cashin, Peter; Söderström, Maria; Blom, Kristin; Artursson, Sara et al.

Part of British Journal of Surgery, p. 1080-1083, 2023

• DOI for Ex vivo assessment of chemotherapy sensitivity of colorectal cancer peritoneal metastases
• Download full text (pdf) of Ex vivo assessment of chemotherapy sensitivity of colorectal cancer peritoneal metastases

Assessment in vitro of interactions between anti-cancer drugs and noncancer drugs commonly used by cancer patients

Andersson, Claes; Ye, Jiawei; Blom, Kristin; Fryknäs, Mårten et al.

Part of Anti-Cancer Drugs, p. 92-102, 2023

• DOI for Assessment in vitro of interactions between anti-cancer drugs and noncancer drugs commonly used by cancer patients
• Download full text (pdf) of Assessment in vitro of interactions between anti-cancer drugs and noncancer drugs commonly used by cancer patients

Ex vivo assessment of cancer drug sensitivity in epithelial ovarian cancer and its association with histopathological type, treatment history and clinical outcome

Bjersand, Kathrine; Blom, Kristin; Sundström Poromaa, Inger; Stålberg, Karin et al.

Part of International Journal of Oncology, 2022

• DOI for Ex vivo assessment of cancer drug sensitivity in epithelial ovarian cancer and its association with histopathological type, treatment history and clinical outcome
• Download full text (pdf) of Ex vivo assessment of cancer drug sensitivity in epithelial ovarian cancer and its association with histopathological type, treatment history and clinical outcome

Single-cell transcriptional pharmacodynamics of trifluridine in a tumor-immune model

Selvin, Tove; Fasterius, Erik; Jarvius, Malin; Fryknäs, Mårten et al.

Part of Scientific Reports, 2022

• DOI for Single-cell transcriptional pharmacodynamics of trifluridine in a tumor-immune model
• Download full text (pdf) of Single-cell transcriptional pharmacodynamics of trifluridine in a tumor-immune model

Sorafenib and nitazoxanide disrupt mitochondrial function and inhibit regrowth capacity in three-dimensional models of hepatocellular and colorectal carcinoma

Nyberg, Frida; Blom, Kristin; Selvin, Tove; Rudfeldt, Jakob et al.

Part of Scientific Reports, 2022

• DOI for Sorafenib and nitazoxanide disrupt mitochondrial function and inhibit regrowth capacity in three-dimensional models of hepatocellular and colorectal carcinoma
• Download full text (pdf) of Sorafenib and nitazoxanide disrupt mitochondrial function and inhibit regrowth capacity in three-dimensional models of hepatocellular and colorectal carcinoma

Melphalan flufenamide inhibits osteoclastogenesis by suppressing proliferation of monocytes

Byrgazov, Konstantin; Lind, Thomas; Rasmusson, Annica J.; Andersson, Claes et al.

Part of Bone Reports, 2021

• DOI for Melphalan flufenamide inhibits osteoclastogenesis by suppressing proliferation of monocytes

Targeting aggressive osteosarcoma with a peptidase-enhanced cytotoxic melphalan flufenamide

Byrgazov, Konstantin; Andersson, Claes; Salzer, Benjamin; Bozsaky, Eva et al.

Part of Therapeutic Advances in Medical Oncology, 2020

• DOI for Targeting aggressive osteosarcoma with a peptidase-enhanced cytotoxic melphalan flufenamide
• Download full text (pdf) of Targeting aggressive osteosarcoma with a peptidase-enhanced cytotoxic melphalan flufenamide

Mebendazole is unique among tubulin-active drugs in activating the MEK-ERK pathway

Andersson, Claes; Selvin, Tove; Blom, Kristin; Rubin, Jenny et al.

Part of Scientific Reports, 2020

• DOI for Mebendazole is unique among tubulin-active drugs in activating the MEK-ERK pathway
• Download full text (pdf) of Mebendazole is unique among tubulin-active drugs in activating the MEK-ERK pathway

Mebendazole-induced M1 polarisation of THP-1 macrophages may involve DYRK1B inhibition

Blom, Kristin; Eriksson, Jenny; Berglund, Malin; Jarvius, Malin et al.

Part of BMC Research Notes, 2019

• DOI for Mebendazole-induced M1 polarisation of THP-1 macrophages may involve DYRK1B inhibition
• Download full text (pdf) of Mebendazole-induced M1 polarisation of THP-1 macrophages may involve DYRK1B inhibition

Self-tuning density estimation based on Bayesian averaging of adaptive kernel density estimations yields state-of-the-art performance

Bäcklin, Christofer; Andersson, Claes; Gustafsson, Mats G

Part of Pattern Recognition, p. 133-143, 2018

• DOI for Self-tuning density estimation based on Bayesian averaging of adaptive kernel density estimations yields state-of-the-art performance

Bliss and Loewe interaction analyses of clinically relevant drug combinations in human colon cancer cell lines reveal complex patterns of synergy and antagonism

Kashif, Muhammad; Andersson, Claes; Mansoori, Sharmineh; Larsson, Rolf et al.

Part of Oncotarget, p. 103952-103967, 2017

• DOI for Bliss and Loewe interaction analyses of clinically relevant drug combinations in human colon cancer cell lines reveal complex patterns of synergy and antagonism
• Download full text (pdf) of Bliss and Loewe interaction analyses of clinically relevant drug combinations in human colon cancer cell lines reveal complex patterns of synergy and antagonism

Targeting tumor cells based on Phosphodiesterase 3A expression

Nazir, Madiha; Senkowski, Wojciech; Nyberg, Frida; Blom, Kristin et al.

Part of Experimental Cell Research, p. 308-315, 2017

• DOI for Targeting tumor cells based on Phosphodiesterase 3A expression

The anticancer effect of mebendazole may be due to M1 monocyte/macrophage activation via ERK1/2 and TLR8-dependent inflammasome activation

Blom, Kristin; Senkowski, Wojciech; Jarvius, Malin; Berglund, Malin et al.

Part of Immunopharmacology and immunotoxicology, p. 199-210, 2017

• DOI for The anticancer effect of mebendazole may be due to M1 monocyte/macrophage activation via ERK1/2 and TLR8-dependent inflammasome activation

Predictive Value of Ex Vivo Chemosensitivity Assays for Individualized Cancer Chemotherapy: A Meta-Analysis

Blom, Kristin; Nygren, Peter; Larsson, Rolf; Andersson, Claes R.

Part of SLAS TECHNOLOGY, p. 306-314, 2017

• DOI for Predictive Value of Ex Vivo Chemosensitivity Assays for Individualized Cancer Chemotherapy: A Meta-Analysis

Large-scale ligand-based predictive modelling using support vector machines

Alvarsson, Jonathan; Lampa, Samuel; Schaal, Wesley; Andersson, Claes et al.

Part of Journal of Cheminformatics, 2016

• DOI for Large-scale ligand-based predictive modelling using support vector machines
• Download full text (pdf) of Large-scale ligand-based predictive modelling using support vector machines

Combination screening in vitro identifies synergistically acting KP372-1 and cytarabine against acute myeloid leukemia

Österroos, Albin; Kashif, Muhammad; Haglund, Caroline; Blom, Kristin et al.

Part of Biochemical Pharmacology, p. 40-49, 2016

• DOI for Combination screening in vitro identifies synergistically acting KP372-1 and cytarabine against acute myeloid leukemia

Ex Vivo Assessment of Drug Activity in Patient Tumor Cells as a Basis for Tailored Cancer Therapy

Blom, Kristin; Nygren, Peter; Alvarsson, Jonathan; Larsson, Rolf et al.

Part of JALA, p. 178-187, 2016

• DOI for Ex Vivo Assessment of Drug Activity in Patient Tumor Cells as a Basis for Tailored Cancer Therapy

In vitro discovery of promising anti-cancer drug combinations using iterative maximisation of a therapeutic index

Kashif, Muhammad; Andersson, Claes; Hassan, Sadia; Karlsson, Henning et al.

Part of Scientific Reports, 2015

• DOI for In vitro discovery of promising anti-cancer drug combinations using iterative maximisation of a therapeutic index
• Download full text (pdf) of In vitro discovery of promising anti-cancer drug combinations using iterative maximisation of a therapeutic index

Benchmarking Study of Parameter Variation When Using Signature Fingerprints Together with Support Vector Machines

Alvarsson, Jonathan; Eklund, Martin; Andersson, Claes; Carlsson, Lars et al.

Part of Journal of Chemical Information and Modeling, p. 3211-3217, 2014

• DOI for Benchmarking Study of Parameter Variation When Using Signature Fingerprints Together with Support Vector Machines

A Pragmatic Definition of Therapeutic Synergy Suitable for Clinically Relevant In Vitro Multicompound Analyses

Kashif, Muhammad; Andersson, Claes; Åberg, Magnus; Nygren, Peter et al.

Part of Molecular Cancer Therapeutics, p. 1964-1976, 2014

• DOI for A Pragmatic Definition of Therapeutic Synergy Suitable for Clinically Relevant In Vitro Multicompound Analyses

Screening for phenotype selective activity in multidrug resistant cells identifies a novel tubulin active agent insensitive to common forms of cancer drug resistance

Fryknäs, Mårten; Gullbo, Joachim; Wang, Xin; Rickardson, Linda et al.

Part of BMC Cancer, p. 374, 2013

• DOI for Screening for phenotype selective activity in multidrug resistant cells identifies a novel tubulin active agent insensitive to common forms of cancer drug resistance
• Download full text (pdf) of Screening for phenotype selective activity in multidrug resistant cells identifies a novel tubulin active agent insensitive to common forms of cancer drug resistance

Synergistic interactions between camptothecin and EGFR or RAC1 inhibitors and between imatinib and Notch signaling or RAC1 inhibitors in glioblastoma cell lines

Sooman, Linda; Ekman, Simon; Andersson, Claes; Kultima, Hanna Göransson et al.

Part of Cancer Chemotherapy and Pharmacology, p. 329-340, 2013

• DOI for Synergistic interactions between camptothecin and EGFR or RAC1 inhibitors and between imatinib and Notch signaling or RAC1 inhibitors in glioblastoma cell lines

A strand specific high resolution normalization method for chip-sequencing data employing multiple experimental control measurements

Enroth, Stefan; Andersson, Claes R.; Andersson, Robin; Wadelius, Claes et al.

Part of Algorithms for Molecular Biology, p. 2, 2012

• DOI for A strand specific high resolution normalization method for chip-sequencing data employing multiple experimental control measurements
• Download full text (pdf) of A strand specific high resolution normalization method for chip-sequencing data employing multiple experimental control measurements

Synergistic Effects of PI3K or P38 MAPK Inhibition in Combination With Vandetanib Treatment in Glioblastoma Cells

Sooman, Linda; Ekman, Simon; Andersson, Claes; Johansson, Fredrik et al.

Part of European Journal of Cancer, 2012

• DOI for Synergistic Effects of PI3K or P38 MAPK Inhibition in Combination With Vandetanib Treatment in Glioblastoma Cells

Brunn: an open source laboratory information system for microplates with a graphical plate layout design process

Alvarsson, Jonathan; Andersson, Claes; Spjuth, Ola; Larsson, Rolf et al.

Part of BMC Bioinformatics, 2011

• DOI for Brunn: an open source laboratory information system for microplates with a graphical plate layout design process
• Download full text (pdf) of Brunn: an open source laboratory information system for microplates with a graphical plate layout design process

Multiplexed Homogeneous Proximity Ligation Assays for High-throughput Protein Biomarker Research in Serological Material

Lundberg, Martin; Thorsen, Stine Buch; Assarsson, Erika; Villablanca, Andrea et al.

Part of Molecular & Cellular Proteomics, 2011

• DOI for Multiplexed Homogeneous Proximity Ligation Assays for High-throughput Protein Biomarker Research in Serological Material

Improving Bayesian credibility intervals for classifier error rates using maximum entropy empirical priors

Gustafsson, Mats G.; Wallman, Mikael; Wickenberg-Bolin, Ulrika; Göransson, Hanna et al.

Part of Artificial Intelligence in Medicine, p. 93-104, 2010

• DOI for Improving Bayesian credibility intervals for classifier error rates using maximum entropy empirical priors

Revealing cell cycle control by combining model-based detection of periodic expression with novel cis-regulatory descriptors

Andersson, Claes R.; Hvidsten, Torgeir R.; Isaksson, Anders; Gustafsson, Mats G. et al.

Part of BMC Systems Biology, p. 45, 2007

• DOI for Revealing cell cycle control by combining model-based detection of periodic expression with novel cis-regulatory descriptors

In vitro drug sensitivity-gene expression correlations involve a tissue of origin dependency

Andersson, Claes R.; Fryknäs, Mårten; Rickardson, Linda; Larsson, Rolf et al.

Part of Journal of chemical information and modeling, p. 239-248, 2007

• DOI for In vitro drug sensitivity-gene expression correlations involve a tissue of origin dependency

Bayesian detection of periodic mRNA time profiles withouth use of training examples

Andersson, Claes R.; Isaksson, Anders; Gustafsson, Mats G.

Part of BMC Bioinformatics, p. 63, 2006

• DOI for Bayesian detection of periodic mRNA time profiles withouth use of training examples

Quantitative Chemogenomics: Machine-Learning Models of Protein-Ligand Interaction

Andersson, Claes R.; Gustafsson, Mats G.; Strömbergsson, Helena

Part of Current Topics in Medicinal Chemistry, p. 1978-1993, 2011

• DOI for Quantitative Chemogenomics: Machine-Learning Models of Protein-Ligand Interaction